Stocks › ABBV
AbbVie Inc.
ABBV·NYSE·
United States·USD
United States·USD$265.76
+2.94 (+1.12%)
Close · Oct 5, 2026 · Close Prices from Tiingo.com
ABBV
AbbVie Inc. · NYSE
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
ABBVS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of ABBV by members of U.S. Congress · 323 on record · 17 in the last 12 months
Whale Activity
Position changes in ABBV reported for 2026-09-30 by 33 tracked institutional filers
- Increased0
- New0
- Held0
- Decreased3
- Closed0
- No prior filing30
| Filer | Shares | Value | Change |
|---|---|---|---|
| FERGUSON WELLMAN CAPITAL MANAGEMENT, INC | 658.1K | $172.2M | — |
| EASTERN BANK | 314.2K | $82.2M | — |
| MassMutual Private Wealth & Trust, FSB | 155.8K | $40.8M | — |
| Violich Capital Management, Inc. | 107.3K | $28.1M | — |
| PARK NATIONAL CORP /OH/ | 96.5K | $25.2M | — |
| Private Capital Advisors, Inc. | 55.9K | $14.6M | — |
| Coastline Trust Co | 46.7K | $12.2M | decreased |
| Iowa State Bank | 44.1K | $11.5M | — |
| Pacific Wealth Management | 38.0K | $10.0M | — |
| TOMPKINS FINANCIAL CORP | 35.5K | $9.3M | — |
| Eastover Investment Advisors LLC | 35.5K | $9.3M | — |
| Legacy Private Trust Co. | 33.4K | $8.7M | — |
KeyVex tracks a curated set of large 13F filers plus the largest positions in recent filings, so this is a sample of institutional activity, not the whole market.
Insider Trading
Net shares bought (+) or sold (−) on the open market by ABBV insiders, by quarter · Form 4
Recent Insider Transactions
1,571 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Donoghoe NicholasEVP, CHIEF BUS/STRAT OFFICER | Sale | −32.7K | $250.00 | $8.2M | Aug 14, 2026 | Form 4 ↗ |
| Quaggin Susan EDirector | Grant / award | +1,118 | $0.00 | $0 | May 8, 2026 | Form 4 ↗ |
| Davis Jennifer L.Director | Grant / award | +1,118 | $0.00 | $0 | May 8, 2026 | Form 4 ↗ |
| MEYER MELODY BDirector | Grant / award | +1,118 | $0.00 | $0 | May 8, 2026 | Form 4 ↗ |
| BURNSIDE WILLIAM H.L.Director | Grant / award | +1,118 | $0.00 | $0 | May 8, 2026 | Form 4 ↗ |
| Hart Brett JDirector | Grant / award | +1,118 | $0.00 | $0 | May 8, 2026 | Form 4 ↗ |
| Roberts Rebecca BDirector | Grant / award | +1,118 | $0.00 | $0 | May 8, 2026 | Form 4 ↗ |
| FREYMAN THOMAS CDirector | Grant / award | +1,118 | $0.00 | $0 | May 8, 2026 | Form 4 ↗ |
| WADDELL FREDERICK HDirector | Grant / award | +1,118 | $0.00 | $0 | May 8, 2026 | Form 4 ↗ |
| FALK THOMAS JDirector | Grant / award | +1,118 | $0.00 | $0 | May 8, 2026 | Form 4 ↗ |
| RAPP EDWARD JDirector | Grant / award | +1,118 | $0.00 | $0 | May 8, 2026 | Form 4 ↗ |
| AUSTIN ROXANNE SDirector | Grant / award | +1,118 | $0.00 | $0 | May 8, 2026 | Form 4 ↗ |
| Purdue David RyanSVP, Controller | Sale | −5,230 | $233.56 | $1.2M | Mar 4, 2026 | Form 4 ↗ |
| Siatis Perry CEVP, GC AND SECRETARY | Sale | −2,600 | $235.26 | $612K | Mar 2, 2026 | Form 4 ↗ |
| Siatis Perry CEVP, GC AND SECRETARY | Sale | −10.3K | $234.66 | $2.4M | Mar 2, 2026 | Form 4 ↗ |
| Siatis Perry CEVP, GC AND SECRETARY | Sale | −5,777 | $233.51 | $1.3M | Mar 2, 2026 | Form 4 ↗ |
| Purdue David RyanSVP, Controller | Tax withholding Amended | −2,108 | $232.08 | $489K | Feb 27, 2026 | Form 4 ↗ |
| Crum Demetris DEVP, CHIEF HR OFFICER | Tax withholding | −1,594 | $232.08 | $370K | Feb 27, 2026 | Form 4 ↗ |
| Purdue David RyanSVP, Controller | Tax withholding | −2,692 | $232.08 | $625K | Feb 27, 2026 | Form 4 ↗ |
| Thakkar RoopalEVP, R&D and CSO | Tax withholding | −8,037 | $232.08 | $1.9M | Feb 27, 2026 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding ABBV · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 56.1M | $14.11B | 0.61% | Jun 30, 2026 |
| VANGUARD 500 INDEX FUND VANGUARD INDEX FUNDS | 45.8M | $11.52B | 0.69% | Jun 30, 2026 |
| iShares Core S&P 500 ETF iShares Trust | 24.3M | $6.12B | 0.69% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P 500(R) ETF Trust | 21.4M | $5.39B | 0.69% | Jun 30, 2026 |
| Fidelity 500 Index Fund Fidelity Concord Street Trust | 22.6M | $4.92B | 0.59% | May 31, 2026 |
| VANGUARD VALUE INDEX FUND VANGUARD INDEX FUNDS | 16.8M | $4.23B | 1.66% | Jun 30, 2026 |
| State Street(R) Health Care Select Sector SPDR(R) ETF SELECT SECTOR SPDR TRUST | 12.5M | $3.14B | 7.74% | Jun 30, 2026 |
| American Mutual Fund | 11.1M | $2.80B | 2.37% | Jul 31, 2026 |
| Capital Income Builder | 10.1M | $2.52B | 1.93% | Jul 31, 2026 |
| VANGUARD DIVIDEND APPRECIATION INDEX FUND VANGUARD SPECIALIZED FUNDS | 10.0M | $2.51B | 1.92% | Jul 31, 2026 |
Mutual funds and ETFs whose N-PORT filings list ABBV's shares (CUSIP 00287Y109), each fund at its latest report since Mar 7, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming abbvie as client
- FEDERAL STREET STRATEGIES, LLCABBVIE, INC. · 2026 Q2 · HCR, MMM$50K
Filing ↗ - TARPLIN, DOWNS & YOUNG, LLCABBVIE INC. · 2026 Q2 · MMM, BUD, HCR$60K
Filing ↗ - ABBVIE, INC.ABBVIE INC. · 2026 Q2 · CPT, HCR, MMM, TAX$1.2M
Filing ↗ - ACG ADVOCACYABBVIE · 2026 Q2 · TRD, CPT$60K
Filing ↗ - WILLIAMS AND JENSEN, PLLCABBVIE, INC. · 2026 Q2 · HCR, MMM, TRD, PHA$30K
Filing ↗
Government Contracts
Federal awards to AbbVie Inc. · USAspending
No federal contract awards found for AbbVie Inc..
U.S. Patents
Recent USPTO applications naming AbbVie Inc.
No USPTO patent applications found for AbbVie Inc..
Annual Financials
From ABBV's 10-K filings · XBRL
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $61.16B | $56.33B | $54.32B | $58.05B | $56.20B |
| Operating income | $15.07B | $9.14B | $12.76B | $18.12B | $17.92B |
| Net income | $4.23B | $4.28B | $4.86B | $11.84B | $11.54B |
| Diluted EPS | $2.36 | $2.39 | $2.72 | $6.63 | $6.45 |
| Operating cash flow | $19.03B | $18.81B | $22.84B | $24.94B | $22.78B |
| Cash and equivalents | $5.23B | $5.52B | $12.81B | $9.20B | $9.75B |
| Total assets | $133.96B | $135.16B | $134.71B | $138.81B | $146.53B |
| Shareholders' equity | -$3.27B | $3.33B | $10.36B | $17.25B | $15.41B |
As AbbVie Inc. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 20, 2026 ↗
Stock Splits
Every split and reverse split in the price history
No stock splits in ABBV's price history.
Material Events (8-K)
Corporate events filed with the SEC
- 8-K · Items 2.02, 9.01Results of operationsOct 5, 2026
EDGAR ↗ - 8-K · Items 7.01, 9.01Reg FD disclosureSep 3, 2026
EDGAR ↗ - 8-K · Items 8.01, 9.01Other eventsAug 18, 2026
EDGAR ↗ - 8-K · Items 8.01, 9.01Other eventsAug 5, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsJul 31, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsJul 6, 2026
EDGAR ↗ - 8-K · Items 7.01, 9.01Reg FD disclosureJun 22, 2026
EDGAR ↗ - 8-K · Items 5.07Shareholder voteMay 12, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsApr 29, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsApr 3, 2026
EDGAR ↗
About AbbVie Inc.
From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersNORTH CHICAGO, IL
IncorporatedDE
SEC CIK0001551152 ↗